

Stepping Stones

2008 was a year of regulatory, commercial and financial achievement, despite market challenges.

And it was a year of change as we began to SHAPE the company around its priorities and future opportunities.

7 regulatory approvals and ...

Cimzia®
Crohn's disease
U.S.
(April 2008)

Keppra® XR
Adjunctive therapy
in epilepsy
U.S.
(September 2008)

Neupro®
Restless legs syndrome
EU
(September 2008)

Vimpat®
Adjunctive therapy
in epilepsy
EU
(September 2008)

Vimpat®
Adjunctive therapy
in epilepsy – U.S.
(October 2008)

Xyzal®
Oral solution antihistamine
U.S.
(February 2008)

Toviaz®
Overactive bladder
U.S., licensed to Pfizer
(October 2008)

... 6 filings

Cimzia®
Rheumatoid arthritis
U.S.
(February 2008)

Cimzia®
Rheumatoid arthritis
EU
(July 2008)

Keppra®
Adjunctive therapy in
epilepsy (infants and
children)
U.S.
(June 2008)

Keppra®
Adjunctive therapy
in epilepsy (infants and
children)
EU
(July 2008)

Keppra®
Adjunctive therapy
in epilepsy – Japan
(November 2008)

Keppra® XR
Adjunctive therapy
in epilepsy
U.S.
(January 2008)

5 launches

Cimzia®
Crohn's disease
U.S. within 48h
(April 2008)

Keppra® XR
Adjunctive therapy
in epilepsy
U.S.
(October 2008)

Vimpat®
Adjunctive therapy
in epilepsy
Germany and U.K.
(September 2008)

Xyzal®
Oral solution
antihistamine
U.S.
(May 2008)

Toviaz®
Overactive bladder EU,
licensed to Pfizer
(June 2008)

Building a strong pipeline

Key products in CNS:
brivaracetam, CDP323

Key products in immunology: Cimzia®
in rheumatoid arthritis,
epratuzumab, CDP7851, CDP6038

Active life-cycle management: Cimzia®,
Keppra®, Neupro®,
Vimpat®, Xyrem®

Implementation of SHAPE

Focus on severe diseases of CNS and immunology

Reallocate resources

Drive **innovation** to deliver solutions for patients

Establish **agile and efficient** organisation

Improve **competitiveness and profitability**

Prioritise **products and markets**

Financials on track

Financial highlights 2008

- Revenue of € 3.6 billion
- Recurring EBITDA of € 733 million
- Net profit of € 42 million reflecting one-time charges related to SHAPE
- Integration of Schwarz Pharma completed

2009 outlook

- Revenue expected of approximately € 3.3 billion
- Recurring EBITDA expected to end the year greater than € 680 million
- Net profit, as reported, expected to exceed € 130 million, excluding the expected capital gains resulting from already announced divestments of early 2009.

